Phenylethylamine (PEA)
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Our verdict OPTIONAL-ADD LOW
Cheap, fast-acting, and the molecule that famously gives chocolate its trace stimulant signature — but the 5-15 min half-life means standalone PEA is essentially useless without a MAO-B inhibitor (selegiline) or a competitive MAO-B substrate (hordenine) to extend it. As a PRN tool stacked with hordenine it is mildly interesting; as a standalone supplement it is mostly placebo. CRITICAL: distinct from palmitoylethanolamide (also abbreviated PEA), which is the anti-inflammatory PEA-Ultra product.
▸ Decision matrix by user profile Per-archetype
| Archetype | Verdict | Rationale |
|---|---|---|
Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype) | OPTIONAL-ADD-PRN | low. Skip; redundant with caffeine + tyrosine and Dylan's V5 modafinil pipeline gives him better daily-stim coverage. |
30-50, executive maintenance | OPTIONAL-ADD-PRN | low. Same. |
50+, mild cognitive decline | OPTIONAL-ADD-PRN | low. Selegiline + PEA depression protocol has minor literature support; would not be first-line. |
Anxiety-prone | SKIP | adrenergic surge can spike anxiety. |
High athletic load, tested status | L | fine — PEA is endogenous and not on WADA list, but pre-workout blends often contain banned stimulants; check labels. |
Sleep-disordered | SKIP | if dosed late. |
Recovery-focused | I | — |
Strength/anabolic-focused | M | pre-workout edge from PEA + hordenine combos; not worth a dedicated slot. |
- Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)OPTIONAL-ADD-PRN
low. Skip; redundant with caffeine + tyrosine and Dylan's V5 modafinil pipeline gives him better daily-stim coverage.
- 30-50, executive maintenanceOPTIONAL-ADD-PRN
low. Same.
- 50+, mild cognitive declineOPTIONAL-ADD-PRN
low. Selegiline + PEA depression protocol has minor literature support; would not be first-line.
- Anxiety-proneSKIP
adrenergic surge can spike anxiety.
- High athletic load, tested statusL
fine — PEA is endogenous and not on WADA list, but pre-workout blends often contain banned stimulants; check labels.
- Sleep-disorderedSKIP
if dosed late.
- Recovery-focusedI
- Strength/anabolic-focusedM
pre-workout edge from PEA + hordenine combos; not worth a dedicated slot.
▸ Subjective experience (deep)
Standalone oral PEA 250-500 mg:
- Onset 5-15 min
- Brief stimulant pulse — focus, mild euphoria, slight body warmth, faster thought
- Crashes equally fast
- Some users report nothing — likely below their dose-response threshold or fast MAO-B metabolizers
- Redosing within 30-60 min produces less effect (depleted vesicular DA/NE)
With hordenine 50-75 mg taken 30 min prior (competitive MAO-B substrate):
- Effect duration extends to 1-3 hours
- Smoother, less pulsey
- More similar to a low-dose stimulant ("amphetamine without the body load")
With selegiline 5 mg:
- Effect can last 4-6 hours
- This is the Sabelli depression protocol
- Stack carries cardiovascular risk — see Drug interactions
▸ Tolerance + cycling deep dive
- Tolerance buildup: Fast acute tolerance within hours (vesicular depletion). True chronic tolerance is less studied because most users don't dose chronically.
- Recommended cycle: PRN only. Daily dosing not informative due to acute tolerance.
- Reset protocol if needed: 24-48 hours off restores acute response.
▸ Stacking deep dive
Synergistic with
- hordenine: Competitive MAO-B substrate that prolongs PEA action without the hypertensive crisis risk of full MAOI. Most popular forum pairing.
- selegiline: True MAO-B inhibitor; biggest extension but biggest risk.
- caffeine, l-tyrosine: Reasonable focus stack — independent mechanisms compound the effect.
Avoid stacking with
- Non-selective MAOIs (phenelzine, tranylcypromine): Hypertensive crisis risk.
- Sympathomimetics (high-dose pseudoephedrine, amphetamines): Additive cardiovascular load.
- Tyramine-rich diet + selegiline: Established interaction — same mechanism as classic MAOI cheese effect.
Neutral / safe co-administration
Magnesium, theanine, glycine, fish oil, V4 daily core compounds.
▸ Drug interactions deep dive
- MAOIs: hypertensive crisis risk (described above)
- SSRIs: theoretical additive serotonergic load — unlikely to produce serotonin syndrome at supplemental PEA doses but caution if also on selegiline
- Stimulant medications: additive cardiovascular effect
▸ Pharmacogenomics
- MAO-B activity polymorphisms affect PEA metabolism rate. Individuals with low-activity MAO-B variants may have longer PEA action (and higher endogenous baseline) — relevant context but not actionable without testing.
▸ Sourcing deep dive
| Path | Vendor | Cost | Reliability | Notes |
|---|---|---|---|---|
| OTC supplement | Bulk Supplements / Nutricost (Amazon) | $10-15 / 100 g | Medium-high | PEA-HCl powder; common pre-workout ingredient |
| OTC supplement | Pre-workout blends (Mr. Hyde, Total War etc.) | varies | Medium | Often paired with hordenine + caffeine + N-methyl-tyramine |
▸ Biomarkers to track (deep)
- Blood pressure (acute) on first stacked dose
- Mood, focus subjective tracking if used for depression-adjacent indication
- Urinary phenylacetic acid (research only; not clinical)
▸ Controversies / open debates Live debate
- The "PEA is the chocolate love drug" trope is overblown — chocolate contains PEA but at doses far below pharmacological threshold; the felt effect of chocolate is more theobromine + sugar + fat + ritual.
- Whether endogenous PEA deficiency contributes to depression or is just a downstream marker is unresolved.
- The Sabelli PEA + selegiline depression result has not been replicated in a modern RCT despite being suggestive — this is a frequently-cited, weakly-supported claim.
▸ Verdict change log
- 2026-05-06 — Initial verdict: OPTIONAL-ADD-PRN low. Standalone PEA is essentially useless; potentiated forms have niche utility but are redundant with Dylan's existing tools.
▸ Open questions / gaps Open
- No modern RCT for PEA + selegiline depression protocol
- Whether PEA + hordenine stack delivers measurable cognitive output benefit vs. placebo in healthy adults (no published trial)
- Long-term safety of chronic PEA + MAO-B inhibitor co-administration
▸ Sources (full, with our context)
- Sabelli & Mosnaim 1974 — Phenylethylamine and depression hypothesis (Am J Psychiatry)
- Sabelli et al. 1996 — PEA + selegiline open-label depression trial (J Clin Psychiatry)
- Borowsky et al. 2001 — TAAR1 receptor identification, PEA as endogenous ligand (PNAS)
- Berry 2004 — Trace amines and TAAR1 review (J Neurochem)
- Janssen et al. 1999 — Plasma PEA pharmacokinetics in humans